Cargando…

Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China

COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas. Data were collected from 178 COVID-19 patients overseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yu-Xuan, Li, Na-Fen, Li, Chen-Yao, Zheng, Fang-Ping, Yao, Xiang-Yang, Lin, Bao-Hua, Huang, Xian-Zhong, Zhao, Neng-Jiang, Yang, Jia-Yong, Chen, Qiu-Min, Zhang, Man-Man, Yi, Li-Tao, Chen, Xue-Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638095/
https://www.ncbi.nlm.nih.gov/pubmed/36353282
http://dx.doi.org/10.3389/fpubh.2022.1038017
_version_ 1784825332048592896
author Huang, Yu-Xuan
Li, Na-Fen
Li, Chen-Yao
Zheng, Fang-Ping
Yao, Xiang-Yang
Lin, Bao-Hua
Huang, Xian-Zhong
Zhao, Neng-Jiang
Yang, Jia-Yong
Chen, Qiu-Min
Zhang, Man-Man
Yi, Li-Tao
Chen, Xue-Qin
author_facet Huang, Yu-Xuan
Li, Na-Fen
Li, Chen-Yao
Zheng, Fang-Ping
Yao, Xiang-Yang
Lin, Bao-Hua
Huang, Xian-Zhong
Zhao, Neng-Jiang
Yang, Jia-Yong
Chen, Qiu-Min
Zhang, Man-Man
Yi, Li-Tao
Chen, Xue-Qin
author_sort Huang, Yu-Xuan
collection PubMed
description COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas. Data were collected from 178 COVID-19 patients overseas at First Affiliated Hospital of Xiamen University from April 1, 2021 to July 31, 2021. These patients received therapy of integrated Chinese medicine and western medicine. Demographic data and clinical characteristics were extracted and analyzed. In addition, the prescription which induced less length of PCR positive days and hospitalization days than the median value was obtained. The top 4 frequently used Chinese medicine and virus-related genes were analyzed by network pharmacology and bioinformatics analysis. According to the chest computed tomography (CT) measurement, abnormal lung findings were observed in 145 subjects. The median length of positive PCR/hospitalization days was 7/7 days for asymptomatic subjects, 14/24 days for mild subjects, 10/15 days for moderate subjects, and 14/20 days for severe subjects. The most frequently used Chinese medicine were Scutellaria baicalensis (Huangqin), Glycyrrhiza uralensis (Gancao), Bupleurum chinense (Chaihu), and Pinellia ternata (Banxia). The putative active ingredients were baicalin, stigmasterol, sigmoidin-B, cubebin, and troxerutin. ACE, SARS-CoV-2 3CL, SARS-CoV-2 Spike, SARS-CoV-2 ORF7a, and caspase-6 showed good binding properties to active ingredients. In conclusion, the clinical results showed that integrated Chinese medicine and Western medicine are effective in treating COVID-19 patients from overseas. Based on the clinical outcomes, the putative ingredients from Chinese medicine and the potential targets of SARS-CoV-2 were provided, which could provide a reference for the clinical application of Chinese medicine in treating COVID-19 worldwide.
format Online
Article
Text
id pubmed-9638095
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96380952022-11-08 Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China Huang, Yu-Xuan Li, Na-Fen Li, Chen-Yao Zheng, Fang-Ping Yao, Xiang-Yang Lin, Bao-Hua Huang, Xian-Zhong Zhao, Neng-Jiang Yang, Jia-Yong Chen, Qiu-Min Zhang, Man-Man Yi, Li-Tao Chen, Xue-Qin Front Public Health Public Health COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas. Data were collected from 178 COVID-19 patients overseas at First Affiliated Hospital of Xiamen University from April 1, 2021 to July 31, 2021. These patients received therapy of integrated Chinese medicine and western medicine. Demographic data and clinical characteristics were extracted and analyzed. In addition, the prescription which induced less length of PCR positive days and hospitalization days than the median value was obtained. The top 4 frequently used Chinese medicine and virus-related genes were analyzed by network pharmacology and bioinformatics analysis. According to the chest computed tomography (CT) measurement, abnormal lung findings were observed in 145 subjects. The median length of positive PCR/hospitalization days was 7/7 days for asymptomatic subjects, 14/24 days for mild subjects, 10/15 days for moderate subjects, and 14/20 days for severe subjects. The most frequently used Chinese medicine were Scutellaria baicalensis (Huangqin), Glycyrrhiza uralensis (Gancao), Bupleurum chinense (Chaihu), and Pinellia ternata (Banxia). The putative active ingredients were baicalin, stigmasterol, sigmoidin-B, cubebin, and troxerutin. ACE, SARS-CoV-2 3CL, SARS-CoV-2 Spike, SARS-CoV-2 ORF7a, and caspase-6 showed good binding properties to active ingredients. In conclusion, the clinical results showed that integrated Chinese medicine and Western medicine are effective in treating COVID-19 patients from overseas. Based on the clinical outcomes, the putative ingredients from Chinese medicine and the potential targets of SARS-CoV-2 were provided, which could provide a reference for the clinical application of Chinese medicine in treating COVID-19 worldwide. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638095/ /pubmed/36353282 http://dx.doi.org/10.3389/fpubh.2022.1038017 Text en Copyright © 2022 Huang, Li, Li, Zheng, Yao, Lin, Huang, Zhao, Yang, Chen, Zhang, Yi and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Huang, Yu-Xuan
Li, Na-Fen
Li, Chen-Yao
Zheng, Fang-Ping
Yao, Xiang-Yang
Lin, Bao-Hua
Huang, Xian-Zhong
Zhao, Neng-Jiang
Yang, Jia-Yong
Chen, Qiu-Min
Zhang, Man-Man
Yi, Li-Tao
Chen, Xue-Qin
Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China
title Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China
title_full Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China
title_fullStr Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China
title_full_unstemmed Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China
title_short Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China
title_sort clinical features and effectiveness of chinese medicine in patients with covid-19 from overseas: a retrospective study in xiamen, china
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638095/
https://www.ncbi.nlm.nih.gov/pubmed/36353282
http://dx.doi.org/10.3389/fpubh.2022.1038017
work_keys_str_mv AT huangyuxuan clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT linafen clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT lichenyao clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT zhengfangping clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT yaoxiangyang clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT linbaohua clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT huangxianzhong clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT zhaonengjiang clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT yangjiayong clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT chenqiumin clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT zhangmanman clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT yilitao clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina
AT chenxueqin clinicalfeaturesandeffectivenessofchinesemedicineinpatientswithcovid19fromoverseasaretrospectivestudyinxiamenchina